STRS Ohio’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History

STRS Ohio’s Portfolio KNTE Stock Details KNTE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-3,300	Closed	-$20K	–	2149
2023 Q1	$20K	Hold	3,300	–	–	﹤0.01%	1869
2022 Q4	$20K	Hold	3,300	–	–	﹤0.01%	1884
2022 Q3	$39K	Hold	3,300	–	–	﹤0.01%	1862
2022 Q2	$41K	Hold	3,300	–	–	﹤0.01%	1886
2022 Q1	$37K	Hold	3,300	–	–	﹤0.01%	1985
2021 Q4	$58K	Hold	3,300	–	–	﹤0.01%	1983
2021 Q3	$75K	Hold	3,300	–	–	﹤0.01%	1994
2021 Q2	$76K	Hold	3,300	–	–	﹤0.01%	2036
2021 Q1	$102K	Buy	+3,300	New	+$115K	﹤0.01%	1938

Other funds holding KNTE

FCMI

Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

FCMV

Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

VVA

Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

STRS Ohio's KNTE Position: Q2 2023 in Review

STRS Ohio sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q2 2023, closing a stake of 3,300 shares — an estimated $20K sold.

STRS Ohio first reported a position in KNTE in Q1 2021 and held it in 9 quarters. The position peaked at $102K in Q1 2021. 72 funds tracked by Wall St. Rank hold KNTE as of Q2 2023.

STRS Ohio reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
STRS Ohio sold 3,300 Kinnate Biopharma Inc. Common Stock shares in Q2 2023, an estimated $20K.
STRS Ohio first reported a position in Kinnate Biopharma Inc. Common Stock in Q1 2021 and held it in 9 quarters.
STRS Ohio's Kinnate Biopharma Inc. Common Stock position peaked at $102K in Q1 2021.
72 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q2 2023.

Based on STRS Ohio's 13F filing for Q2 2023, filed 31 Jul 2023.